Turkey Oncology Clinical Trials Market Report 2022 to 2030

Turkey Oncology Clinical Trials Market Analysis

$ 3999

Turkey's oncology clinical trials market is projected to grow from $101.2 Mn in 2022 to $161.3 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the country's expanding healthcare infrastructure and increased emphasis on R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Deva Holding.

ID: IN10TRCT006 CATEGORY: Clinical Trials GEOGRAPHY: Turkey AUTHOR: Vidhi Upadhyay

Buy Now

Turkey Oncology Clinical Trials Market Executive Summary

Turkey's oncology clinical trials market is projected to grow from $101.2 Mn in 2022 to $161.3 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. According to data provided by clinicaltrials.gov, 903 clinical studies were launched in Türkiye between September 1, 2021, and September 1, 2022. Neurology has the highest proportion (105), followed by oncology (95) and orthopedics (71). According to current data from Invest in Turkey, Turkey accounted for around 1.5% of the global pharmaceutical industry in 2020. In Turkey, the most prevalent types of cancer in males are trachea, bronchial, and lung cancer, whereas lung cancer is the fourth most common kind of cancer in women. According to the data by Globocan 2020, in Turkey, there were 2,33,834 new incidences of cancer with 1,26,335 fatalities.

Turkey has taken part in a variety of international oncology clinical studies. These studies are looking at novel therapies for breast cancer, lung cancer, and leukaemia. Turkey has also carried out clinical studies for the development of novel cancer treatments. The Turkish Ministry of Health has created clinical trial guidelines and regulations, including those for oncology trials. These principles guarantee that clinical trials are carried out ethically and with patient safety as a top priority. In order to facilitate clinical trials, the Turkish Ministry of Health fosters partnerships between universities, hospitals, and research institutions. Turkey has boosted its involvement in clinical trials in recent years, and the nation is becoming an increasingly appealing place for conducting studies owing to its huge patient population and reduced expenses compared to Western countries. Additionally, Turkey's strategic position between Europe and Asia makes it an attractive venue for international clinical trials.

turkey oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

One of the major elements is the country's expanding healthcare infrastructure and increased emphasis on R&D. The Turkish government has invested in the construction of research facilities and hospitals, which has assisted in attracting foreign pharmaceutical firms to perform clinical trials in the country. Moreover, Turkey's vast patient population is a significant motivator for conducting clinical trials, since it allows for quicker patient recruitment and more reliable findings. Another driver is that clinical trials in Turkey are less expensive than in Western nations. Turkey's cost advantage has made it an appealing venue for international clinical trials, especially for corporations trying to lower their R&D expenses.

Market Restraints

The regulatory environment, which may be complicated and time-consuming, is one of these constraints. Businesses may have difficulties in gaining required clearances and licenses, which might hold down the clinical trial procedure. Moreover, there may be difficulties in finding and maintaining skilled healthcare professionals and research personnel in Turkey. Although the country's healthcare infrastructure is improving, there is still a scarcity of skilled cancer specialists and clinical trial coordinators. This scarcity may impede the expansion of clinical trials in the nation.

Competitive Landscape

Key Players

Pfizer Inc.
Roche Holding AG
Novartis International AG
AstraZeneca plc
Merck & Co., Inc.
Abdi İbrahim (TUR)
Deva Holding (TUR)
Nobel İlaç (TUR)
Mustafa Nevzat İlaç Sanayii (TUR)

Notable Insights

December 2021, RS Research wants to extend its trial pipeline with a $12 Mn investment in targeted cancer drug delivery. In Turkey, the biotech is presently developing one medication, a possible therapy for non-small cell lung cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.